Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Milnacipran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 10/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 9/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | HTR2C | P28335 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levomilnacipran SCHEMBL16163256 | 1.00 | SLC6A2 (1.00) | SLC6A2KDM4EMAPK1SLC6A4SLC6A3 | |
| 1R,2S-Milnacipran SCHEMBL4434769 | 1.00 | SLC6A2 (1.00) | SLC6A2KDM4EMAPK1SLC6A4SLC6A3 | |
| Levomilnacipran SCHEMBL1289763 | 1.00 | SLC6A2 (1.00) | SLC6A2KDM4EMAPK1SLC6A4SLC6A3 | |
| Levomilnacipran SCHEMBL1148742 | 1.00 | SLC6A2 (1.00) | SLC6A2KDM4EMAPK1SLC6A4SLC6A3 | |
| 1R,2S-Milnacipran SCHEMBL161558 | 1.00 | SLC6A2 (1.00) | SLC6A2KDM4EMAPK1SLC6A4SLC6A3 | |
| 1R,2S-Milnacipran SCHEMBL8099 | 0.99 | SLC6A2 (1.00) | SLC6A2KDM4EMAPK1SLC6A4SLC6A3 | |
| Levomilnacipran SCHEMBL12027608 | 0.99 | SLC6A2 (1.00) | SLC6A2KDM4EMAPK1SLC6A4SLC6A3 | |
| 1R,2S-Milnacipran SCHEMBL30083111 | 0.99 | SLC6A2 (1.00) | SLC6A2KDM4EMAPK1SLC6A4SLC6A3 | |
| Milnacipran SCHEMBL114034 | 0.99 | SLC6A2 (1.00) | SLC6A2KDM4EMAPK1SLC6A4SLC6A3 | |
| Levomilnacipran SCHEMBL1707471 | 0.99 | SLC6A2 (1.00) | SLC6A2KDM4EMAPK1SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12241889-B2 | Malate to detect and as a target for fibromyalgia | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2025-03-04 | — | — | US | claimed |
| WO-2025024501-A1 | NEUROMODULATORY PEPTIDES | LACTOCORE, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| CN-113573723-B | Synthetic neuromodulatory peptides | 拉托科公司 | 2024-12-03 | — | — | CN | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-20240307386-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. | 2024-09-19 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | ANEUROTECH BV (BE) | 2023-11-30 | — | — | US | claimed |
| US-20230140798-A1 | SYNTHETIC PEPTIDES DIRECTED AGAINST THE METABOTROPIC GLUTAMATE RECEPTOR 5 | LACTOCORE INC (US) | 2023-05-04 | — | — | US | claimed |
| EP-4135741-A1 | SYNTHETIC PEPTIDES FOR MODULATING THE METABOTROPIC GLUTAMATE RECEPTOR 5 | Lactocore, Inc. (US) | 2023-02-22 | — | — | EP | claimed |
| CN-115379847-A | Synthetic peptides for modulating metabotropic glutamate receptor 5 | 拉托科公司 | 2022-11-22 | — | — | CN | claimed |
| US-20220175873-A1 | SYNTHETIC NEUROMODULATORY PEPTIDES | LACTOCORE, INC. | 2022-06-09 | — | — | US | claimed |
| US-20220065846-A1 | MALATE TO DETECT AND AS A TARGET FOR FIBROMYALGIA | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2022-03-03 | — | — | US | claimed |
| US-RE43879-E1 | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug | PIERRE FABRE MEDICAMENT (FR) | 2012-12-25 | — | — | US | claimed |
| WO-2012046247-A2 | PROCESS FOR THE PREPARATION OF (±M1R(S), 2SRR)L-2-(AMINOMETHYL)-N,N-DIETHYL-L-PHENYLCYCLOPROPANE CARBOXAMIDE HYDROCHLORIDE | MSN LABORATORIES LIMITED (IN) | 2012-04-12 | — | — | WO | claimed |
| US-7943785-B2 | Process for producing (Z)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2- phthalimidomethylcyclopropane | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-17 | — | — | US | claimed |
| EP-1845084-B1 | PROCESS FOR PRODUCING (Z)-1-PHENYL-1-(N,N-DIETHYLAMINOCARBONYL)IDOMETHYLCYCLOPROPANE | SUMITOMO CHEMICAL CO (JP) | 2011-04-20 | — | — | EP | claimed |
| US-20090292127-A1 | Process for Producing (Z)-1-Phenyl-1-(N,N-Diethylaminocarbonyl)-2-Phthalimidomethylcyclopropane | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-11-26 | — | — | US | claimed |
| US-7592485-B2 | Process for producing (Z)-1-phenyl-1-diethylaminocarbonyl-2-aminomethylcyclopropane hydrochloride | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-09-22 | — | — | US | claimed |
| EP-1845084-A1 | PROCESS FOR PRODUCING (Z)-1-PHENYL-1-(N,N-DIETHYLAMINOCARBONYL)IDOMETHYLCYCLOPROPANE | Sumitomo Chemical Company, Limited (JP) | 2007-10-17 | — | — | EP | claimed |
| US-7005452-B2 | administering enantiomorphs comprising (Z(+-)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride), as serotonin and adrenergic uptake inhibitors, with side effect reduction; antidepressants | PIERRE FABRE MEDICAMENT (FR) | 2006-02-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292127-A1 | Process for Producing (Z)-1-Phenyl-1-(N,N-Diethylaminocarbonyl)-2-Phthalimidomethylcyclopropane | BPNT1, CPN1, PNN | SLC6A2 2105/4885SLC6A4 2288/4885KDM4E 2006/4885 |
| US-20240307386-A1 | NOVEL METHODS | OPRL1, HTR2A, OPRM1 | SLC6A2 174/4885SLC6A4 86/4885KDM4E 2886/4885 |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | HTR2A, HTR3B, HTR5A | SLC6A2 44/4885SLC6A4 25/4885KDM4E 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.